(Bloomberg) — Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion) as the Swiss pharma company starts following through on plans to use bolt-on acquisitions to beef up its pipeline. Most Read from Bloomberg The Swiss drugmaker will pay €68 a share in cash for the German biotech maker of cancer treatments, […]
Novartis (NVS) agreed late Monday to buy German drugmaker MorphoSys (MOR) for roughly $2.9 billion, and the biotech stock catapulted to a nearly three-year high.
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the promising heart-drug developer. The biotech company, currently running a sale process, leaves room for speculation on whether Novartis or another suitor might re-emerge or if the company will explore alternative options such as a […]
Updated Jan. 11, 2024 12:47 pm ET Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer. The Swiss drug giant had been closing in on a purchase of South San Francisco-based Cytokinetics, with an agreement expected as soon as this week, […]
Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as pharmaceutical companies companies continue to snap up fast-growing biotechs to replenish their pipelines. A purchase by the Swiss drug company of South San Francisco-based Cytokinetics, which has a market value of about $9 […]
Novartis (NVS) expanded its gene therapy collaboration with Voyager Therapeutics (VYGR) on Monday. VYGR stock rocketed above its 200-day line for the first time in four months.
(Reuters) -Voyager Therapeutics said on Tuesday Swiss-based drugmaker Novartis would pay $100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders. Voyager, whose shares jumped more than 30% in premarket trading, would be eligible to receive up to $1.2 billion on achieving certain milestones. The gene therapy developer […]